AbbVie - Recruiting 18 years to 70 years. - A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
Merck Sharp & Dohme Corp. - Recruiting 18 years to 65 years. - A Multiple Dose Study to Evaluate Pharmacokinetics and Hepatitis C Virus RNA Dynamics Following Administration of MK-5172 in Hepatitis C Infected Patients.
Hologic, Inc. - Recruiting 18 years or older. - Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay.
Institut de Recherche pour le Developpement - Recruiting 18 years or older. - Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization..
Yale University - Recruiting 3 Months to 50 years. - De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation.
Pediatric transplant subject with d-AIH; Pediatric transplant subject with acute rejection; Pediatric transplant subject with chronic rejection; Adult non-transplant patients with auto-immune hepatitis; Adult non-transplant subjects with chronic hepatitis C virus; Pediatric control subjects
Merck Sharp & Dohme Corp. - Recruiting 18 years or older. - A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ñ Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection.
Novartis - Recruiting N/A or older. - Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients.
Erasmus Medical Center - Recruiting 18 years or older. - Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial..
Janssen R&D Ireland - Recruiting 18 years or older. - A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study..
SYZ Cell Therapy Co.. - Recruiting 20 years to 70 years. - Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens.
MASCT:Multiple Antigens Specific Cellular Therapy; The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment
Bristol-Myers Squibb - Recruiting 18 years or older. - A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C.
University of North Carolina, Chapel Hill - Recruiting 18 years or older. - CIDRZ-1220 Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA).
Valme University Hospital - Recruiting 18 years or older. - Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort..
Bristol-Myers Squibb - Recruiting 18 years or older. - A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Nave or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin.
Gilead Sciences - Recruiting 18 years to 79 years. - A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment.
AbbVie - Recruiting 18 years to 80 years. - A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection.
Hopital Lariboisire - Recruiting 18 years or older. - Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL.
University of Roma La Sapienza - Recruiting 40 years to 70 years. - Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano.
Janssen R&D Ireland - Recruiting 18 years to 70 years. - A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients.
AbbVie - Recruiting 18 years to 75 years. - An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Nave and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II).
University of Florida - Recruiting 18 years or older. - Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1.
Fundacion SEIMC-GESIDA - Recruiting 18 years or older. - Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir.
University of Zurich - Recruiting 18 years or older. - A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS).
University Hospital, Limoges - Recruiting 18 years or older. - Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus..
The Leeds Teaching Hospitals NHS Trust - Recruiting 18 years to 65 years. - A Clinical Study to Evaluate the Biological Effects of Administering Rimantadine in Patients With Hepatitis C Virus (HCV) Infection Alongside Standard Combination Therapy With Pegylated Interferon and Ribavirin.
ChronTech Pharma AB - Recruiting 18 years to 65 years. - A Phase II Open-Label, Randomized, Parallel Group, Safety, Tolerability and Efficacy Study of i.m. Administered CHRONVAC-C in Combination With Electroporation Followed by Standard of Care in Chronic Hepatitis C Virus Genotype 1 Infected and Treatment Nave Subjects.
National Taiwan University Hospital - Recruiting 50 years to 70 years. - Functional Genomics and Proteomics Towards and Understanding of Cell Signaling and Diseases--- Genomic and Proteomic Analyses of Liver Cells During Hepatitis Virus Infections and Cell Therapy (4/4).